Search VCEL
Vericel Corp
Nasdaq · CIK 887359
Last close40.15
Daily change+0.71 (1.80%)
10 Years gain+1354.71%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
VCEL · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
74.9Momentum
100.0Acceleration
99.6Confidence
90.0Annual Revenue17
Quarterly Revenue63
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth22.3 / 25
Quality21.5 / 25
Capital Efficiency8.7 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.7 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 3.0824 percentage points.
Operating leverageOperating margin improved by 10.2304 percentage points.
ROIC expansionROIC improved by 9.7869 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM29%OK
Revenue CAGR 3Y19.06%OK
Gross Margin72.97%OK
Operating Margin-2.24%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-2.12%OK
Incremental Operating Margin 3Y14.32%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y4.82%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $276.26M | $205.60M | $11.04M | $51.91M | $24.75M | 74.42% | 4% | 8.96% | 5.34% | 52.15M |
| 2025 FY Dec 31, 2024 | $237.22M | $172.11M | $4.52M | $58.16M | -$5.81M | 72.55% | 1.91% | -2.45% | 3.05% | 51.68M |
| 2025 FY Dec 31, 2023 | $197.52M | $135.58M | -$6.46M | $35.31M | $15.30M | 68.64% | -3.27% | 7.75% | -5.4% | 47.59M |
| 2024 FY Dec 31, 2022 | $163.70M | $109.79M | -$17.06M | $17.69M | $10.09M | 67.07% | -10.42% | 6.16% | -19.28% | 47.13M |
| 2023 FY Dec 31, 2021 | $153.08M | $106.03M | -$7.85M | $29.04M | $21.13M | 69.26% | -5.13% | 13.8% | -9.89% | 46.47M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $276.63M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-050836, 0001628280-25-049902 |
| Revenue Growth TTM | 29% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-050836, 0001628280-25-049902 |
| Revenue CAGR 3Y | 19.06% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012013 |
| Revenue CAGR 5Y | 17.76% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-012013 |
| Gross Profit CAGR 3Y | 23.26% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012013 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-050836, 0001628280-25-049902 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 72.97% | Gross Profit / Revenue | OK | 0001628280-26-050836, 0001628280-25-049902 |
| Operating Margin | -2.24% | Operating Income / Revenue | OK | 0001628280-26-050836, 0001628280-25-049902 |
| ROIC | -2.12% | NOPAT / Average Invested Capital | OK | 0001628280-26-050836, 0001628280-25-049902 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-050836 |
| Current Ratio | 5.04x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $5.29 | Revenue / Diluted Shares | OK | 0001628280-26-050836, 0001628280-25-049902 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |